Amalgamated Bank Grows Stock Position in Masimo Corporation $MASI

Amalgamated Bank increased its holdings in shares of Masimo Corporation (NASDAQ:MASI) by 5.2% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 21,743 shares of the medical equipment provider’s stock after purchasing an additional 1,081 shares during the quarter. Amalgamated Bank’s holdings in Masimo were worth $3,658,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Masimo by 0.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider’s stock worth $1,894,000 after acquiring an additional 66 shares during the last quarter. Assetmark Inc. increased its stake in Masimo by 5.0% during the second quarter. Assetmark Inc. now owns 1,539 shares of the medical equipment provider’s stock worth $259,000 after acquiring an additional 73 shares during the last quarter. Xponance Inc. increased its stake in Masimo by 1.1% during the first quarter. Xponance Inc. now owns 7,101 shares of the medical equipment provider’s stock worth $1,183,000 after acquiring an additional 76 shares during the last quarter. Deutsche Bank AG increased its stake in Masimo by 1.5% during the first quarter. Deutsche Bank AG now owns 6,309 shares of the medical equipment provider’s stock worth $1,051,000 after acquiring an additional 92 shares during the last quarter. Finally, State of Michigan Retirement System increased its stake in Masimo by 1.0% during the first quarter. State of Michigan Retirement System now owns 10,596 shares of the medical equipment provider’s stock worth $1,765,000 after acquiring an additional 100 shares during the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Masimo

In other Masimo news, Director William R. Jellison purchased 3,000 shares of Masimo stock in a transaction that occurred on Monday, August 11th. The stock was purchased at an average price of $145.98 per share, with a total value of $437,940.00. Following the completion of the acquisition, the director owned 4,790 shares of the company’s stock, valued at approximately $699,244.20. This trade represents a 167.60% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 9.70% of the stock is owned by insiders.

Masimo Price Performance

Shares of NASDAQ MASI opened at $140.65 on Monday. Masimo Corporation has a 1-year low of $133.70 and a 1-year high of $194.88. The business has a 50-day moving average of $144.80 and a 200-day moving average of $154.12. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.14 and a quick ratio of 1.61. The company has a market capitalization of $7.64 billion, a price-to-earnings ratio of -16.51 and a beta of 1.28.

Masimo (NASDAQ:MASI) last issued its earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share for the quarter. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%.The company had revenue of $617.00 million during the quarter. On average, equities analysts anticipate that Masimo Corporation will post 4.1 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on MASI shares. Zacks Research lowered Masimo from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 24th. Weiss Ratings restated a “sell (d)” rating on shares of Masimo in a research note on Wednesday, October 8th. Piper Sandler upped their price target on Masimo from $200.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 6th. Wall Street Zen upgraded Masimo from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Finally, BTIG Research restated a “buy” rating and set a $198.00 price target on shares of Masimo in a research note on Thursday, September 11th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $194.60.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.